Big 5 Sporting Goods (NASDAQ:BGFV) reported $238.30 million in sales this quarter. This is a 12.82 percent decrease over sales of $273.36 million the same period last year.
Seres Therapeutics Announces FDA Acceptance Of Biologics License Application For Investigational Microbiome Therapeutic SER-109 For Recurrent C. Difficile Infection For Priority Review
– If approved, SER-109 expected to be the first-ever FDA-approved oral microbiome therapeutic –
– PDUFA target action date is April 26, 2023, with anticipated launch soon thereafter –
–
